stockrow
Saturday 7 November 2026
Export MDXG’s income statement to Excel — free account
MiMedx Group, Inc
MDXG Healthcare Biotechnology
MiMedx Group, Inc’s revenue for fiscal 2025 (year ended December 2025) was $418.6 million, up 20.0% from fiscal 2024.
- Revenue
- −45.2%
- EPS
- −154.1%
- Free cash flow
- −87.2%
- Total debt
- −6.80%
Quarter to September 2026, against a year earlier
3.31
0.03
+0.91%
Follow MDXG
Alert me
| Sep '26 | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 96.25 | 18.81 | 20.52 |
+8 more quarters Free account |
P/S ratio |
2.24 | 1.60 | 1.51 | 2.39 | |
P/FCF ratio |
35.73 | 12.81 | 8.46 | 13.71 | |
P/Operating CF |
173.45 | (56.82) | 312.06 | 40.09 | |
P/B ratio |
3.22 | 2.63 | 2.41 | 3.90 | |
Price to Tangible BV |
3.77 | 3.08 | 2.79 | 4.49 | |
EV/Sales |
1.90 | 1.27 | 1.14 | 2.04 | |
EV/EBITDA |
0.00 | 22.07 | 8.40 | 10.82 | |
EV/Operating CF |
27.78 | 9.76 | 6.29 | 11.52 | |
EV/FCF |
30.29 | 10.14 | 6.41 | 11.68 | |
Quick Ratio |
3.67 | 4.60 | 4.62 | 3.76 | |
Current Ratio |
4.35 | 5.33 | 5.39 | 4.32 | |
Net Debt/EBITDA |
11.80 | 7.01 | 9.85 | (6.10) | |
Debt/Assets |
0.00% | 6.12% | 5.70% | 5.24% | |
Debt/Equity |
0.00 | 0.08 | 0.07 | 0.07 | |
Asset Turnover |
1.04 | 1.24 | 1.34 | 1.38 | |
Operating CF/Net income |
(0.45) | 0.67 | (0.17) | 1.64 | |
Capex/Depreciation |
(0.13) | (0.41) | (0.40) | (0.08) | |
Research and Development Expense of Revenue |
4.49% | 4.31% | 7.02% | 4.03% | |
Selling, General and Administrative Expense of Revenue |
93.63% | 92.88% | 90.24% | 61.88% | |
Intangible Assets out of Total Assets |
0.12 | 0.11 | 0.11 | 0.10 | |
Share Based Compensation of Revenue |
5.16% | 1.40% | (2.88%) | 2.09% | |
Graham Net Nets |
0.20 | 0.25 | 0.30 | 0.19 | |
Graham Number |
0.00 | 1.15 | 2.78 | 3.59 | |
Earnings Yield |
(2.78%) | 1.04% | 5.32% | 4.87% | |
Free Cash Flow Yield |
2.80% | 7.81% | 11.82% | 7.29% | |
Revenue per Share |
0.43 | 0.44 | 0.40 | 0.80 | |
Operating CF per Share |
0.03 | (0.07) | 0.01 | 0.17 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.03 | (0.07) | 0.01 | 0.17 | |
Cash per Share |
0.83 | 0.92 | 1.08 | 1.12 | |
Shareholders Equity per Share |
1.45 | 1.46 | 1.64 | 1.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.45 | 1.46 | 1.64 | 1.74 | |
Free Cash Flow |
3.73 | (10.65) | 1.24 | 24.71 | |
Working Capital |
144.20 | 166.87 | 195.78 | 213.21 | |
Capital Expenditures |
(0.19) | (0.63) | (0.64) | (0.25) | |
Net Current Asset Value |
133.76 | 140.37 | 174.59 | 191.37 | |
EV/EBIT |
0.00 | 51.47 | 11.22 | 13.34 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.00 | |
Price to Operating Income |
0.00 | 65.02 | 14.81 | 15.66 | |
| Other line items | |||||
Average Receivables |
57.73 | 55.26 | 54.16 | 65.77 | |
Average Payables |
11.62 | 8.40 | 10.17 | 10.97 | |
Average Inventory |
24.30 | 22.91 | 25.15 | 24.57 | |
Average Assets |
291.77 | 286.05 | 289.55 | 303.28 | |
Average Common Equity |
225.01 | 216.31 | 222.86 | 224.83 |
Columns are period end dates · fundamentals updated 2 Nov 2026